{"name":"3E Therapeutics Corporation","slug":"3e-therapeutics-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQajF5MUNsd0IyX1V1RTlGZE10UDhCQWNRWkZOTXRlcHZMa1Z3ODdqNkRidW5RLURnWFl4QWpkbkI2RnllLV9uVEk5bTVWNUdjSE1hQWJkU0NyM2NlVDlmRkt5aE9hbGtHSE40MVFudzdTb2QtdjIwWW9pMDhPbVhKVjF1T2ZOcGw0RVgzT2lVTDY0RXdYNnFzWjdKRkJZdEg5eXc?oc=5","date":"2026-01-06","type":"deal","source":"BioPharma Dive","summary":"Amgen buys protein-degrading startup Dark Blue for up to $840M - BioPharma Dive","headline":"Amgen buys protein-degrading startup Dark Blue for up to $840M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOQkxmbk12TjRSRXhEVnFZTGotcy1sUlZsYXdPSTNBeV9BTk40QnJraDBzeHppNGpuR0JLVmk3TV82a0drdXhTdUpGOTgzMk5DbVdlclZYMTQzSzlfelE1eTdwYXpGVXBNMzV6eW05ZjBPLTFTMHF5TUNscEVlTkhqWQ?oc=5","date":"2025-12-19","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds - Fierce Biotech","headline":"Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPcU1vQkdtY05jMWY3SUI5OTFyRC12Rm8yZ0RZckEtUlFNSVliVEVGcVowdUlMTlI0NHQzRF9FdGg5aGdnNndIWVYzN0FaQnNDcG1rR3VZTkg5YTNNSXRtVHlHUjNHb3NfSUNOVmJ3cGM4UElaemhRSEt3QXZ3NkVScVNuOWF2U0pWUjhYSEtHZ2FVMDRvN1A1cmFjUVlQLU5hVGI4c2d4TGM0bGw0UGM0TGVCRUprazlhbmZBbw?oc=5","date":"2025-09-16","type":"deal","source":"European Biotechnology Magazine","summary":"Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal - European Biotechnology Magazine","headline":"Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPejVMS0t2NkpSRkZCMXZGZk9wMlowSk1CN09pTkdvZlgzMElOX25sWG04VFpDdXdoamxOeE9JZkh1THl3QS1tZ2gwLWFiSjdsYUpoMkJsbHBaak5VcEdHdUNiaFRrQUt2OG4yQjUwSHRydW42S0pUb1NuQVdNdkNlUnhxZ1FUTXB4MlBEVFBacWUyc0Q0YTVOTjJYNVRoS0xSQXFaODdJZDFjTnc?oc=5","date":"2025-08-25","type":"pipeline","source":"Fierce Biotech","summary":"Arnatar unveils with $52M, dual-modality RNA platform and rare disease asset - Fierce Biotech","headline":"Arnatar unveils with $52M, dual-modality RNA platform and rare disease asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQVFzRGxpRTF4X2xqZEdYSVh0MmlvUWY5aldoY0tsN011Uy0wZDViZXc5UEttZ1hRei1OQ25SVUlWajZaekJqSFVEMXZmYWhVTG1oVVVUXzFMb1ZzNkl4R2dmV0tuZTRrZTdyblNYeGE1ODFoQWEwT2M4TWlwbFg5VFZacDlKcjFYU19fenplUHJMaVp5eEo0cEdDbEMwdHNJd2tvTWNkaGNmb3JIX3lzQ3ZCcEVxWmpZZWhr?oc=5","date":"2025-03-01","type":"pipeline","source":"Seeking Alpha","summary":"Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025 - Seeking Alpha","headline":"Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOZjYwbklrS0dFNERFOXV2eW1rRXlZWkRkU1hRREZLZDUzeUZORExqTnpaRmJXYi1aclE2OVFLRVZRSVQ1SVRlX2hWaVZQUlhRcEsySFdVV0J0akFpQXJFQXY4ZExWaDNhbmI0b0FLUEExSGZEcXpmaE9ZUFhnd3p6QWRhcGNpVHhmZ0U3aGVWcDN2V0tia09jNVdQX3VQUDJncWpEd0NBcnRoVWxmWldFcUdyVG9jMW9lMXdHVXMyQ1laUzVKN0RncDlMUlhRSFJqOC0xYlpDM3k0YWNNQTdzTjl1SldDQ1V3ZGtrQlY5b1k5Ym9icWprbDdaYkkxU1BHUzR0V1g4VTNzRW05REdWamJsVnowMmJzaU9nMkMwU2pjSVNP?oc=5","date":"2024-07-11","type":"trial","source":"PR Newswire","summary":"Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire","headline":"Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPMDVaa2VWZVkxcm82UHFBeUtub285OFBOMzhzMVlMOENoUXY2SThZSm15dFl1alJ1UGptWkQ1NzZYMDFCcV96WE9zYVlyTmh2TnNYQ0p3aFVYV0xxNEJiSXNLYkFaR3dmdGM1ckxPZTBPUENqOWVObW45M3hINWFJUzR1MU1BSWdIV1c0TXR1S1Jidw?oc=5","date":"2024-04-18","type":"pipeline","source":"Pharmaceutical Technology","summary":"Outrun Therapeutics announces launch with $10m seed funding - Pharmaceutical Technology","headline":"Outrun Therapeutics announces launch with $10m seed funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE01Y053RTNMX3c4eXgtbEZzR3BMdXpwSUI1UG4wVDVnUDJzNWROQmpXa0dDNVUtMlVjZmVROWVSbG5abWZzWGNoRVhjSFRiTXNMMGxrQTFrUURtTDRsTEtJ?oc=5","date":"2023-11-01","type":"pipeline","source":"nature.com","summary":"Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides - nature.com","headline":"Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5vNmtvYndSVGJYamM3VkQxZjZQNHYwZGxOZzhjek1tbWptQWRrLWtNVzhxbUkxdTRRRDM3eVFCSGN0emt6VlpNOWJaNlpWVXNLaXpILUIwOTVCTnE0eFlRb25vdDNoMHc0cnc?oc=5","date":"2023-07-12","type":"pipeline","source":"Wiley Online Library","summary":"Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework - Wiley Online Library","headline":"Alzheimer's disease diagnostic accuracy by fluid and neuroimaging ATN framework","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPSnhDRk4xNDF3eERKaDYyaGNPejlqREhKWHZmMEJtYVZ1cnhEWlNBcmR1dElGV0hiYktINzJEcVdTSEoyWTUxZjFZRi1Mc1Y1b2J3WlkxVXVIQWQzN3p0UnNuOHJERnI0VUdyYlNDM19Cc2plM1BKWlFBS3hJbHZORmtVME9DNm0yeXRqaEdQTGUzNFhjN0NRcTlGem5vUnFjeU56NUMxQXJtd3RsUDVlQTN6MVdlMkxZQmVsLWZDd3Nqb3dad19SSU9mT04wYkh0V2pmY21WMGFrWjBudjZuOGFmMy13WnFYMy16Vy10QW1SeElEdlFhZllZeW5xSUVWX095dnppVmFRRU1zTHF3bmFrNWRBcEszcmlNMFk5MDNxem81dFowZnhn?oc=5","date":"2022-08-24","type":"trial","source":"businesswire.com","summary":"Regenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B Financing - businesswire.com","headline":"Regenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPdzMxOXFSTHFnb3E5c2hlRURhVUJtZnJRSEFlUmpaRlBtUnlBME1XRUJwVEhSSzBEc2pzN2pfRXp5N3IyRmFtWEwteTh6dTVUb2lDTXFmcW4zeWRIdC1FVlFRY3pWakcyMHNRTk1raGZQRTNvN3dCSEZtUFlXTGF5SVZQTEZuQTJjTnBnS3lORjN3WktjR25WZHdnYnpGRzRTVFZyWG1hOVEySHRQYWsyUU4yZ194WHJ4ZWx4OGZSNFlRLXB3djJveHl2UXRzMXpDUnZmSjB1QzRlNFdBRTJiOTFFNE1CRmdEcmEtQndteXJ5NlNOR0RtOUh4Um9jQ2ZVVWJGU2p2VkZHNFZ0UHc?oc=5","date":"2022-01-18","type":"trial","source":"PR Newswire","summary":"Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials - PR Newswire","headline":"Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9lUENkMEhNN0tfMTZrOWoxam9YLUFDNUtkTFlrMHljcEprV2NpMWQ4c1NPWDRJdHNRN3AxYkZRc1JydDdZWUl3bmcwYjcySXRUOGw1dF9xc1Jfa0JVR0hoa3Rvb3VaVnVFZURSMkhKSUhRQW5xWHVMMw?oc=5","date":"2020-03-26","type":"pipeline","source":"BioSpace","summary":"Regenacy Pharma Earns $30 Million Series A to Advance Diabetic Neuropathy Drug - BioSpace","headline":"Regenacy Pharma Earns $30 Million Series A to Advance Diabetic Neuropathy Drug","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}